Mirum registers Phase 1 ADME trial for MRM-3379 in healthy male volunteers
Mirum Pharmaceuticals listed a new Phase 1 study tracking how the body absorbs, distributes, metabolizes and excretes radiolabeled MRM-3379.
Mirum Pharmaceuticals had one notable registry update this week.
- Mirum registered a Phase 1, open-label trial (NCT07712718) examining the absorption, distribution, metabolism, and excretion of radiolabeled MRM-3379 following a single oral dose in healthy male participants1. The study is recruiting, with an estimated enrollment of 8 participants and a primary completion date estimated for July 20261.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.